RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors
© Oronsky et al. 2016
Received: 27 October 2015
Accepted: 4 May 2016
Published: 11 May 2016
The tumor-specific microregional effects of the anticancer agent RRx-001, a novel epigenetic-based radio/chemosensitizer with nitrogen oxide-donating properties in phase II clinical trials, were investigated with whole tissue section quantitative immunohistological staining in mouse SCCVII and human U87 tumors.
SCCVII tumors exhibited regions of intermittent perfusion exemplified by co-localization of vessels with the hypoxia marker pimonidazole commonly occurring throughout the tissue. A moderate increase in perfusion (21 to 28 %) was observed after a bolus dose of the perivascular stain DiOC7(3), however, with the absence of an increase in tissue oxygenation. U87 tumors showed an absence of blood flow over large areas of treated tumors after dosing with RRx-001. However, these areas did not become necrotic and returned to near normal levels after 12 h. No significant change in tumor hypoxia was seen at 90 min or 12 h. For both tumor types, RRx-001 treatment resulted in the loss of perfusion in the large regions of the tumor; however, at the 12-h time point, both tumor types showed an increase in vessel perfusion but no significant decrease in hypoxia.
These data suggest a redistribution of blood flow within the tumor for both tumor types akin to vascular normalization. Differences between the tumors were related to tumor architecture and distribution of alpha-smooth muscle actin (α-SMA). RRx-001 shows promise for short-term blood flow redistribution in tumors with a pericyte- and α-SMA-rich vasculature. Expression of α-SMA in tumor vasculature could therefore be useful for predicting tumor response to RRx-001.
The tumor microenvironment has been compared to a neighborhood . In such an analogy, the “slums” represented by the poorly perfused, marginalized, necrotic center of the tumor could be contrasted with the better-differentiated “suburbia” of the periphery with a transition zone in between them. However, equating the periphery with high status and centrality with low status is oversimplified given the diversified pattern of “hot spots” of hypoxia and perfusion throughout the core of the tumor due to variations in vasculature development . These “pockets of decay” in the tumor based on the mismatched forces of supply and demand have led to supply side antiangiogenic/antivascular strategies to push these hypoxic areas to the tipping point of eradication. However, efforts at eradication inevitably meet with difficulty and/or failure because their insularity in the tumor microenvironment transforms them into “fortresses” that are difficult for chemotherapy to penetrate.
The tumor microenvironment is a catch-all term to denote a “local” set of “neighborhood” conditions, which includes hypoxia status and the architecture of the vasculature. The hallmark of the microenvironment is heterogeneity with thinly divided, cheek-by-jowl zones of wealth and poverty in terms of blood flow and oxygenation. The driver of this heterogeneity is hypoxia-induced neovasculogenesis and metastatic dissemination, which arguably is secondary to the maturity of the vasculature. Two main categories of hypoxia are present in tumors: chronic hypoxia, also known as diffusion-limited or permanent hypoxia, and acute hypoxia, also known as perfusion-limited or transient hypoxia .
Vasodilator-unresponsive microvessels devoid of smooth muscle actin coverage are prone to intermittent collapse or compression, leading to acute or transient hypoxia. Acutely induced hypoxic stress may enhance the potential metastatic efficiency of the tumor to a greater degree than prolonged exposure to hypoxia since transiently hypoxic cells have the advantage of proximity to functional blood vessels and a higher energy status than chronically hypoxic cells .
Given the nocivity of acute hypoxia, in terms of its role in tumor aggressiveness, an alternative strategy to the hypoxia-exacerbating effects of antiangiogenesis is a redistribution of the blood supply from immature vessels, where blood flow is already sluggish or stagnant, to more mature blood vessels, thereby normalizing blood flow.
Results and discussion
For both tumor types, RRx-001 appeared to cause the loss of perfusion in the large regions of the tumor; however, at the 12-h time point, both tumor types showed an increase in vessel perfusion but no overall decrease in hypoxia: Indeed, while overall changes in perfusion and hypoxia are mild, local changes within the tumor were found to be dramatic. In contrast to previous work that demonstrated increases in RRx-001-mediated bulk tumor blood flow in SCCVII tumors by contrast-enhanced ultrasound (CEUS) , these data suggest a redistribution of blood flow in both tumor types while differences between the tumors were related to tumor architecture and distribution of alpha-smooth muscle actin (α-SMA).
In the rhetoric of urban space, the tumor microenvironment is a heterogeneous yet integrated co-op neighborhood etched with boundaries and borderlands that intersect, overlap, collide, and coexist along lines drawn and redrawn by quirks of intricate capillary network geometries, leading to the heterogeneity of oxygen delivery and the associated oxygen gradients.
The areas with the greatest metastatic potential may not be the down-and-out “skid row” population of chronically ischemic cells but the still-viable population of acutely hypoxic cells proximate to a mature vascular network and transiently enriched with oxygen.
Antiangiogenic or antivascular strategies that inhibit the existing or the neovasculature may only serve to increase the hypoxic fraction and, thus, the metastatic efficiency of the tumor.
In contrast, the antitumor and antiproliferative effects of the novel epigenetic inhibitor, RRx-001, may be ascribed to a relative change or reorganization of blood flow within the tumor. This conclusion is supported by the macroscopic appearance of poorly perfused and hypometabolic areas in the SCCVII and U87 tumors without an increase in the overall hypoxic fraction post-RRx-001 treatment.
RRx-001-modified red blood cells selectively home to and obstruct morphologically immature and hypoxic tumor vessels, leading to a compensatory redistribution of blood flow through more mature smooth muscle pericyte-covered vessels, akin to vascular normalization. This normalization, which has been demonstrated preclinically and clinically, improves the delivery of cytotoxic chemotherapy and radiosensitizing oxygen, improving tumor control.
SCCVII tumors are characterized by a more mature angioarchitecture than U87 xenografts. The hypothesized effect of RRx-001 on SCCVII tumors is a multifocal, diffuse vasoconstriction with a uniform redistribution of blood flow in contrast to the focally vasoconstricted U87 tumors with moth-eaten cell-lucent areas.
Although contrast-enhanced ultrasound detected changes in bulk tumor blood flow in SCCVII tumors after RRx-001 administration suggesting a provascular effect , the data presented herein demonstrate a significant but temporary loss of perfusion with no significant concomitant change in the level of hypoxia, suggesting a redistribution of blood flow within the tumor. Differences in the local nature of the effect between the two tumor types can be attributed to tumor architecture.
The binary view of pharmacologic blood flow modulation as either pro- or antivascular should be amended to include strategies of redistribution . Just like the rehabilitation of “low rent” neighborhoods characterized by overcrowding and marginalization, the redistributive strategy posits that the marginal, acutely hypoxic regions of the tumor can be revitalized or normalized instead of demolished, thereby reducing the oxygen asymmetry and the hypoxic potential for angiogenesis and metastatic dissemination.
The tumor microenvironment should not be viewed as homogenous masses of cancer cells but rather mixtures of cell populations with varying levels of heterogeneity that respond differently to different vascular modification strategies. Diagnostic imaging and histopathologic examination in the setting of vascular normalization open a window to the particular structural and biochemical characteristics of each tumor for treatment optimization and improved patient outcomes.
RRx-001 used in these studies was obtained from EpicentRx, Inc. RRx-001 is a cyclic nitro compound with molecular formula of C5H6BrN3O5, molecular weight of 268.02, and chemical structure depicted in Fig. 1. The synthesis and characterization of RRx-001 is reported in detail elsewhere .
The methods in this study were carried out in accordance with approved guidelines (including ARRIVE and the Canadian Council on Animal Care guidelines) and the relevant institutional review boards (IRB) at the University of California San Diego (UCSD), and British Columbia Cancer Research Centre approved the experimental protocols.
Mice and tumors
Female C3H/Hen mice and female NOD.CB17-Prkdcscid/J mice were bred and maintained in the British Columbia Cancer Research Centre animal facility in accordance with the Canadian Council on Animal Care guidelines. The mice were allowed free access to standard laboratory rodent food and water. Tumor cells (SCCVII: 0.5 × 106 cells in 50 μL; U87: 5 × 106 cells in 50 μL) were implanted sub-cutaneously into the sacral region. The mice were administered RRx-001, 15 mg/kg IV, in a single dose when tumors reached ~150 mm3 as calculated from caliper measurement of three orthogonal diameters (a, b, c) using the formula volume = π/6(abc). Each arm of an experiment contained six mice. The mice were administered 1000 mg/kg BrdUrd i.p. and 60 mg/kg pimonidazole i.p. (Hypoxyprobe-1 Kit, Chemicon International Inc., Temecula, CA, USA) and euthanized 1 h later. Five minutes prior to carbon dioxide euthanasia and tumor harvest, the mice were administered 50 μL of 0.6 mg/mL DiOC7(3) in 25 % DMSO. Tumors were then excised, weighed, and immediately frozen.
Immunohistochemistry. Group 1: DiOC7(3), CD31, pimonidazole, and BrdUrd
Prior to immunostaining, the slides were imaged for DiOC7(3) tissue fluorescence to visualize blood flow. Cryosections were fixed in a 1:1 mixture of acetone-methanol for 10 min at room temperature. Vasculature was stained using a 1:400 dilution of rat-anti-CD31 (BD 553370) and 1:200 fluorescent Alexa 488 anti-rat secondary (Invitrogen, Burlington, ON, CA). Hypoxia was detected via bound pimonidazole adducts using a 1:500 polyclonal rabbit anti-pimonidazole (Hypoxyprobe) and a 1:200 Alexa 546 anti-rabbit secondary. Cellular DNA was counterstained with Hoechst 33342. The slides were imaged for fluorescence and then transferred to distilled water for 10 min and then treated with 2 M HCl at room temperature for 1 h followed by neutralization for 5 min in 0.1 M sodium borate. The slides were then washed in distilled water and transferred to a PBS (phosphate buffered saline) bath. BrdUrd incorporated into DNA was detected using a 1:200 dilution of monoclonal mouse anti-BrdUrd (clone BU33) followed by 1:200 Alexa 647 anti-rabbit secondary.
Immunohistochemistry. Group 2: DiOC7(3), CD31, and HIF1-α
Cryosections were fixed in a 1:1 mixture of acetone-methanol for 10 min at room temperature. Vasculature was stained using a 1:400 dilution of rat-anti-CD31 (BD 553370) and 1:200 fluorescent Alexa 546 anti-rat secondary (Invitrogen, Burlington, ON, CA). HIF1-α was detected using a 1:500 dilution of a rabbit anti-HIF1-α antibody (Cayman, 10006421) detected via a 1:200 Alexa 647 anti-rabbit secondary. Cellular DNA was counterstained with Hoechst 33342.
The imaging system consists of a robotic fluorescence microscope (Zeiss Axioimager Z1, Oberkochen, Germany), a cooled, monochrome CCD camera (Retiga 4000R, QImaging, Vancouver, BC, Canada), a motorized slide loader and x-y stage (Ludl Electronic Products, Hawthorne, NY, USA), and customized ImageJ software (public domain program developed at the US National Institutes of Health, available at http://rsb.info.nih.gov/ij/) running on a Macintosh computer (Apple, Cupertino, CA, USA). The system allows tiling of adjacent microscope fields of view. Using this system, images of entire tumor cryosections 1–3 cm2 were captured at a resolution of 0.75 μm/pixel.
Image analysis: tumor mapping
Using NIH-ImageJ and user-supplied algorithms, images were overlaid and the areas of necrosis and staining artifacts were manually removed. On the fluorescence images, CD31-, BrdUrd-, and HIF1-α-positive regions were identified using a fixed threshold. For CD31, areas less than 9 μm2 in size were considered artifacts and automatically removed from the analysis. Average HIF1-α-positive staining and average pimonidazole/HIF1-α intensity were calculated from the images of the entire tumor sections following removal of the necrotic regions and tissue artifacts (folds, tears, debris, etc). The fraction of the CD31 vessels that were positive for DiOC7 was calculated based on a 50 % coverage by area of each CD31 object. Pimonidazole profiles in relation to tumor vasculature were calculated by measuring the distance from each point in the tissue to the nearest CD31-positive object and noting the pimonidazole intensity at that point. This data was then tabulated so as to determine the average pimonidazole staining intensity of all pixels found at each distance to a blood vessel.
Statistical analysis was conducted using GraphPad Prism (La Jolla, CA) using one-way ANOVA tests. The significance of differences between multiple groups was compared using a Bonferroni post-test analysis.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Danovi SA. Tumour microenvironment: there goes the neighbourhood. Nat Rev Cancer. 2008;8:908–9. doi:10.1038/nrc2556.View ArticleGoogle Scholar
- Chaudary N, Hill RP. Hypoxia and metastasis. Clin Cancer Res. 2007;13:1947. doi:10.1158/1078-0432.CCR-06-2971.View ArticlePubMedGoogle Scholar
- Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;1(125):5591–6. doi:10.1242/jcs.116392.View ArticleGoogle Scholar
- Rofstad EK, Gaustad JV, Egeland TAM, Mathiesen B, Galappathi K. Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination. Int J Cancer. 2010;127(7):1535–46.View ArticlePubMedGoogle Scholar
- Scicinski J, Oronsky B, Ning S, Minchinton A, Knox S. RRx-001 modulates intratumor blood flow in SCCVII and U87 tumors. Cancer Res. 2012;72(8):Suppl 1 (4371). Proceedings: AACR 103rd Annual Meeting 2012– Mar 31-Apr 4, 2012; Chicago, IL.Google Scholar
- Huxham LA, Kyle AH, Baker JHE, Nykilchuk LK, Minchinton AI. Microregional effects of gemcitabine in HCT-116 xenografts. Cancer Res. 2004;64:653. doi:10.1158/0008-5472.CAN-04-0986.View ArticleGoogle Scholar
- Ning S, Bednarski M, Oronsky B, Scicinski J, Saul G, Knox SJ. Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res. 2012;14:2600.View ArticleGoogle Scholar
- Sonveaux P. Provascular strategy: targeting functional adaptations of mature blood vessels in tumors to selectively influence the tumor vascular reactivity and improve cancer treatment. Radiother Oncol. 2008;86(3):300–13.View ArticlePubMedGoogle Scholar
- Oronsky B, Reid T, Knox SJ, Scicinski J. Beyond antiangiogenesis: vascular modulation as an anticancer therapy—a review. Trans Oncol. 2012;5(3):133–40.View ArticleGoogle Scholar
- Straessler NA, Lesley MW, Cannizzo LF. Development of a safe and efficient two-step synthesis for preparing 1-bromoacetyl-3, 3-dinitroazetidine, a novel clinical anticancer candidate. Org Process Res Dev. 2012;16:512–7.View ArticleGoogle Scholar